Volume 11 Supplement 1

5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Open Access

A novel pathway of cGMP

  • Michaela Kuhn1Email author,
  • Beatrice Dankworth1,
  • Martin Kruse2,
  • Michael Hartmann1,
  • Viacheslav O Nikolaev3,
  • Katharina Völker1,
  • Birgit Gaßner1,
  • Robert Feil4,
  • Marc Freichel5,
  • Olaf Pongs2 and
  • Michael Klaiber1
BMC Pharmacology201111(Suppl 1):O28

https://doi.org/10.1186/1471-2210-11-S1-O28

Published: 1 August 2011

Background

Cardiac atrial natriuretic peptide (ANP) regulates arterial blood pressure, moderates cardiomyocyte growth, and stimulates angiogenesis and metabolism. ANP binds to the transmembrane guanylyl cyclase (GC) receptor, GC-A to exert its diverse functions. This involves a cGMP-dependent signaling pathway preventing pathological [Ca2+]i raises in myocytes. In chronic cardiac hypertrophy, however, ANP levels are markedly increased and GC-A/cGMP responses to ANP are blunted due to receptor desensitization.

Results

Here we show that in this situation ANP binding to GC-A stimulates a novel cGMP-independent signaling pathway in cardiac myocytes, resulting in pathologically elevated intracellular Ca2+ levels ([Ca2+i]). This pathway involves the activation of TRPC3/C6 Ca2+ channels (transient receptor potential canonical channel 3/6) by GC-A which forms a stable complex with TRPC3/C6 channels. Our results indicate that the resulting TRPC3/C6-mediated Ca2+ entry then stimulates Calmodulin Kinase II (CaMKII) to phosphorylate L-type Ca2+ channels leading to increased L-type Ca2+ channel mediated Ca2+ current and a rise in intracellular Ca2+ levels.

Conclusion

These observations reveal a dual role of the ANP/GC-A signaling pathway in the regulation of cardiac myocyte Ca2+i-homeostasis. Under physiological conditions, activation of a cGMP-dependent pathway moderates the Ca2+i-enhancing action of hypertrophic factors such as Angiotensin II. By contrast, a cGMP-independent pathway predominates under pathophysiological conditions, when GC-A is desensitized by high ANP levels. The concomitant rise in [Ca2+i] is likely to increase the propensity to cardiac hypertrophy and arrhythmias.

Authors’ Affiliations

(1)
Institute of Physiology, University of Würzburg
(2)
Institut für Neurale Signalverarbeitung, Universität Hamburg
(3)
Institute of Pharmacology, University of Würzburg
(4)
Interfakultäres Institut für Biochemie, Universität Tübingen
(5)
Experimentelle und Klinische Pharmakologie und Toxikologie, Universität des Saarlandes

Copyright

© Kuhn et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement